STATEN
ISLAND, N.Y., Nov. 1, 2022
/PRNewswire/ -- Acurx Pharmaceuticals, Inc. (NASDAQ: ACXP) ("Acurx"
or the "Company"), a clinical stage biopharmaceutical company
developing a new class of antibiotics for difficult-to-treat
bacterial infections, announced today that the Company will release
its 2022 third quarter financial results on Monday, November 14, 2022, at 8:30 am ET before the U.S. financial markets
open.
David P. Luci, President and
Chief Executive Officer, and Robert G.
Shawah, Chief Financial Officer, will host a conference call
to discuss the results and provide a business update as
follows:
Date:
|
Monday, November 14,
2022
|
|
|
Time:
|
8:30 a.m. ET
|
|
|
Toll free
(U.S.):
|
877-790-1503
|
|
|
International:
|
Click here for
participant international Toll-Free access numbers
|
|
https://www.incommconferencing.com/international-dial-in
|
|
|
Conference
ID:
|
13733824
|
|
|
About Ibezapolstat
Ibezapolstat is a novel, orally administered antibiotic being
developed as a Gram-Positive Selective Spectrum (GPSS™)
antibacterial. It is the first of a new class of DNA
polymerase IIIC inhibitors under development by Acurx to treat
bacterial infections. Ibezapolstat's unique spectrum of
activity, which includes C. difficile but spares other
Firmicutes and the important Actinobacteria phyla, appears to
contribute to the maintenance of a healthy gut microbiome.
The Company successfully completed Phase 1 and Phase 2a clinical
trials of ibezapolstat. The Phase 2a trial demonstrated 100%
clinical cure and 100% sustained clinical cure in patients with
C. difficile Infection (CDI), along with beneficial
microbiome changes during treatment including overgrowth of
Actinobacteria and Firmicutes phylum species while on therapy and
new findings which demonstrate potentially beneficial effects on
bile acid metabolism. Acurx is currently enrolling patients
in its Phase 2b vancomycin-controlled
efficacy study in a 1:1 randomized, non-inferiority trial of a
total of 64 patients with CDI.
In June 2018, ibezapolstat was
designated by the U.S. Food and Drug Administration (FDA) as a
Qualified Infectious Disease Product (QIDP) for the treatment of
patients with CDI and will be eligible to benefit from the
incentives for the development of new antibiotics established under
the Generating New Antibiotic Incentives Now (GAIN) Act. In
January 2019, FDA granted "Fast
Track" designation to ibezapolstat for the treatment of patients
with CDI. The CDC has designated C. difficile as an
urgent threat highlighting the need for new antibiotics to treat
CDI.
About Acurx Pharmaceuticals,
Inc.
Acurx Pharmaceuticals is a clinical stage biopharmaceutical
company focused on developing new antibiotics for difficult to
treat infections. The Company's approach is to develop antibiotic
candidates that target the DNA polymerase IIIC enzyme and its
R&D pipeline includes antibiotic product candidates that target
Gram-positive bacteria, including Clostridioides difficile,
methicillin-resistant Staphylococcus aureus (MRSA),
vancomycin resistant Enterococcus (VRE) and drug-resistant
Streptococcus pneumoniae (DRSP).
To learn more about Acurx Pharmaceuticals and its product
pipeline, please visit www.acurxpharma.com.
Forward-Looking
Statements
Any statements in this press release about our future
expectations, plans and prospects, including statements regarding
our strategy, future operations, prospects, plans and objectives,
and other statements containing the words "believes,"
"anticipates," "plans," "expects," and similar expressions,
constitute forward-looking statements within the meaning of The
Private Securities Litigation Reform Act of 1995. Actual results
may differ materially from those indicated by such forward-looking
statements as a result of various important factors, including:
whether ibezapolstat will benefit from the QIDP designation;
whether ibezapolstat will advance through the clinical trial
process on a timely basis; whether the results of the clinical
trials of ibezapolstat will warrant the submission of applications
for marketing approval, and if so, whether ibezapolstat will
receive approval from the FDA or equivalent foreign regulatory
agencies where approval is sought; whether, if ibezapolstat obtains
approval, it will be successfully distributed and marketed; and
other risks and uncertainties described in the Company's annual
report filed with the Securities and Exchange Commission on Form
10-K for the year ended December 31,
2021, and in the Company's subsequent filings with the
Securities and Exchange Commission. Such forward-looking statements
speak only as of the date of this press release, and Acurx
disclaims any intent or obligation to update these forward-looking
statements to reflect events or circumstances after the date of
such statements, except as may be required by law.
Investor Contact:
Acurx Pharmaceuticals, Inc.
David P. Luci, President &
CEO
Tel: 917-533-1469
Email: davidluci@acurxpharma.com
View original
content:https://www.prnewswire.com/news-releases/acurx-pharmaceuticals-inc-to-discuss-2022-third-quarter-financial-results-on-november-14-2022-conference-call-and-provide-business-update-301664443.html
SOURCE Acurx Pharmaceuticals, Inc.